Co88BV59H21-2V67-66 (ATCC® CRL-11539)

Organism: Homo sapiens, human  /  Cell Type: B lymphoblast; Epstein-Barr virus (EBV) transforme  /  Disease: Cancer

Permits and Restrictions

View Permits

Organism Homo sapiens, human
Cell Type B lymphoblast; Epstein-Barr virus (EBV) transforme
Product Format frozen
Morphology lymphoblast
Culture Properties suspension
Biosafety Level 2 Cells contain Epstein-Barr Virus DNA Sequences
Disease Cancer
Applications
This transformed cell line was derived from B-cells of a patient undergoing surgical resection of colorectal cancer.
Peripheral blood mononuclear cells (PBMNC) were transformed with Epstein-Barr virus (EBV) derived from the B95-8 marmoset cell line.
Co88BV59H21-2V67-66 cells produce monoclonal antibody 88BV59 that has been shown to recognize colon tumor associated antigen (CTAA) 16.88, also referred to as CTA #1.
The CO 88BV59 cell line was fused with a human-mouse heteromyeloma to produce a cell line designated Co88BV59H21-2 (ATCC CRL-11538).
Co88BV59H21-2 was then exposed to EBV under conditions suitable for transformation to produce Co88BV59H21-2V67-66 (ATCC CRL-11539).
Karyotype diploid
Derivation
This transformed cell line was derived from B-cells of a patient undergoing surgical resection of colorectal cancer. The patient was actively immunized with autologous tumor antigen.
Peripheral blood mononuclear cells (PBMNC) were transformed with Epstein-Barr virus (EBV) derived from the B95-8 marmoset cell line.
The CO 88BV59 cell line was fused with a human-mouse heteromyeloma to produce a cell line designated Co88BV59H21-2 (ATCC CRL-11538).
Clinical Data
This transformed cell line was derived from B-cells of a patient undergoing surgical resection of colorectal cancer.
Comments
This transformed cell line was derived from B-cells of a patient undergoing surgical resection of colorectal cancer. The patient was actively immunized with autologous tumor antigen.
Peripheral blood mononuclear cells (PBMNC) were transformed with Epstein-Barr virus (EBV) derived from the B95-8 marmoset cell line.
Co88BV59H21-2V67-66 cells produce monoclonal antibody 88BV59 that has been shown to recognize colon tumor associated antigen (CTAA) 16.88, also referred to as CTA #1.
Both the 88BV59 antibody and the 16-88 antibody recognize the same tumor associated antigen, but react with different epitopes on that antigen.
The 16-88 antibody (LiCO 16-88) is available as ATCC HB-8495.
The CO 88BV59 cell line was fused with a human-mouse heteromyeloma to produce a cell line designated Co88BV59H21-2 (ATCC CRL-11538).
Co88BV59H21-2 was then exposed to EBV under conditions suitable for transformation to produce Co88BV59H21-2V67-66 (ATCC CRL-11539).
Subculturing
Medium Renewal: Every 2 to 3 days
Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 8 X 10 exp5 viable cells/ml.
Maintain cell density between 5 X 10 exp5 and 2 X 10 exp6 viable cells/ml.
Cryopreservation
culture medium 95%; DMSO, 5%
Culture Conditions
Temperature: 37.0°C
Isotype IgG3; kappa light chain
Name of Depositor Organon Teknika Biotech Research Institute
References

Hanna M Jr., et al. Tumor associated monocoloal antibodies derived from human B-cell line. US Patent 4,997,762 dated Mar 5 1991

Hanna MG Jr., et al. Tumor associated monoclonal antibodies. US Patent 5,474,755 dated Dec 12 1995

Butler SM, et al. Tumor associated epitope. US Patent 5,951,985 dated Sep 14 1999

De Jager R, et al. Current status of cancer immunodetection with radiolabeled human monoclonal antibodies. Semin. Nucl. Med. 23: 165-179, 1993. PubMed: 8511602

Moffat FL Jr., et al. Preoperative scintigraphy and operative probe scintimetry of colorectal carcinoma using technetium-99m-88BV59. J. Nucl. Med. 36: 738-745, 1995. PubMed: 7738642

Serafini AN, et al. Radioimmunoscintigraphy of recurrent, metastatic, or occult colorectal cancer with technetium 99m-labeled totally human monoclonal antibody 88BV59: results of pivotal, phase III multicenter studies. J. Clin. Oncol. 16: 1777-1787, 1998. PubMed: 9586891

Wolff BG, et al. Radioimmunoscintigraphy of recurrent, metastatic, or occult colorectal cancer with technetium Tc 99m 88BV59H21-2V67-66 (HumaSPECT-Tc), a totally human monoclonal antibody. Patient management benefit from a phase III multicenter study. Dis. Colon Rectum 41: 953-962, 1998. PubMed: 9715149

Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
References

Hanna M Jr., et al. Tumor associated monocoloal antibodies derived from human B-cell line. US Patent 4,997,762 dated Mar 5 1991

Hanna MG Jr., et al. Tumor associated monoclonal antibodies. US Patent 5,474,755 dated Dec 12 1995

Butler SM, et al. Tumor associated epitope. US Patent 5,951,985 dated Sep 14 1999

De Jager R, et al. Current status of cancer immunodetection with radiolabeled human monoclonal antibodies. Semin. Nucl. Med. 23: 165-179, 1993. PubMed: 8511602

Moffat FL Jr., et al. Preoperative scintigraphy and operative probe scintimetry of colorectal carcinoma using technetium-99m-88BV59. J. Nucl. Med. 36: 738-745, 1995. PubMed: 7738642

Serafini AN, et al. Radioimmunoscintigraphy of recurrent, metastatic, or occult colorectal cancer with technetium 99m-labeled totally human monoclonal antibody 88BV59: results of pivotal, phase III multicenter studies. J. Clin. Oncol. 16: 1777-1787, 1998. PubMed: 9586891

Wolff BG, et al. Radioimmunoscintigraphy of recurrent, metastatic, or occult colorectal cancer with technetium Tc 99m 88BV59H21-2V67-66 (HumaSPECT-Tc), a totally human monoclonal antibody. Patient management benefit from a phase III multicenter study. Dis. Colon Rectum 41: 953-962, 1998. PubMed: 9715149